Ascendis Pharma A-S

Ascendis Pharma’s warrant exercise boosts capital to accelerate its growth‑hormone pipeline—investors watch how the liquidity lift drives new milestones and shares stay near $229.

Ascendis Pharma insider holdings show confidence: Fairey William holds 2,117 shares, while execs keep “holding” stakes, hinting at future upside if clinical milestones succeed.

Ascendis Pharma’s insider RSU activity signals strong confidence in its once‑weekly growth‑hormone platform, backed by promising clinical data and potential market upside.